References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2018-4-47-53

mrj-861

Research Article

ОБЗОРЫ

REVIEWS

Обоснованный подход к выбору нестероидных противовоспалительных препаратов при остеоартрите

A sound approach to choosing nonsteroidal anti-inflammatory drugs for osteoarthritis

Зонова

Е. В.

Zonova

E. V.

Елена Владимировна Зонова.

630091, Новосибирск, Красный проспект, 52.

Elena Vladimirovna Zonova.

52, Krasnyi Prospect, Novosibirsk 630091.

elena_zonova@list.ru

Каратеев

А. Е.

Karateev

A. E.

1ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России.РоссияNovosibirsk State Medical University, Ministry of Health of Russia.Russian Federation

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».РоссияV.A. Nasonova Research Institute of Rheumatology.Russian Federation

2018

06122018

1244753

2018

Зонова Е.В., Каратеев А.Е.

Zonova E.V., Karateev A.E.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/861

Современные правила назначения обезболивающей терапии при остеоартрите (ОА) основываются на новейших знаниях о патогенезе этого заболевания и механизме действия анальгетических средств. Ведущий принцип выбора анальгетиков – оценка природы боли и состояния пациента, а также возможности развития нежелательных реакций. Это непосредственно касается нестероидных противовоспалительных препаратов (НПВП), которые сегодня являются важнейшим классом обезболивающих средств, используемых при ОА. Среди препаратов этого класса следует выделить мелоксикам – представитель группы оксикамов, который в относительно равной степени ингибирует циклооксигеназу 1 и 2, а также влияет на активность микросомальной простагландин Е2 синтетазы 1. Этот препарат отличают доказанная эффективность и благоприятный профиль безопасности. Тем не менее необходимость многофакторной оценки осложнений терапии должна быть признана приоритетной при использовании любых НПВП.

The current guidelines for prescribing analgesic therapy for osteoarthritis (OA) are based on the latest knowledge about the pathogenesis of this disease and the mechanism of action of analgesics. The leading principle of choosing analgesics is to assess the nature of pain and the patient's condition, adverse drug reactions. This is directly related to nonsteroidal anti-inflammatory drugs (NSAIDs) that are now the most important class of painkillers used in OA. Among the drugs of this class, meloxicam, a representative of the oxicam group, which relatively equally inhibits cyclooxygenase 1 and 2 and also affects the activity of microsomal prostaglandin E2 synthase 1, should be identified. This drug is characterized by a proven efficacy and a favorable safety profile. Nevertheless, the need for multifactorial evaluation of treatment-associated complications should be recognized as a priority when using any NSAIDs.

остеоартритлечениенестероидные противовоспалительные препаратыэффективностьбезопасностьмелоксикам

osteoarthritistreatmentnonsteroidal anti-inflammatory drugsefficacysafetymeloxicam

References1

Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. doi: 10.1016/j.semarthrit.2015.11.009. Epub 2015 Dec 2.

Bastick AN, Belo JN, Runhaar J, Bierma-Zeinstra SM. What Are the Prognostic Factors for Radiographic Progression of Knee Osteoarthritis? A Metaanalysis. Clin Orthop Relat Res. 2015 Sep;473(9):2969-89. doi: 10.1007/s11999-015-4349-z. Epub 2015 May 21.

De Rooij M, van der Leeden M, Heymans MW, et al. Prognosis of Pain and Physical Functioning in Patients With Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2016 Apr;68(4):481-92. doi: 10.1002/acr.22693.

Driban JB, Price LL, Eaton CB, et al. Individuals with incident accelerated knee osteoarthritis have greater pain than those with common knee osteoarthritis progression: data from the Osteoarthritis Initiative. Clin Rheumatol. 2016 Jun;35(6):1565-71. doi: 10.1007/s10067-015-3128-2. Epub 2015 Nov 27.

Paladini A, Fusco M, Coaccioli S, et al. Chronic Pain in the Elderly: The Case for New Therapeutic Strategies. Pain Physician. 2015 Sep-Oct;18(5):E863-76.

Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study. PLoS One. 2014 Mar 7;9(3):e91286. doi: 10.1371/journal.pone.0091286. eCollection 2014.

Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160-7. doi: 10.1016/j.semarthrit.2016.04.002. Epub 2016 Apr 13.

Veronese N, Stubbs B, Solmi M, et al. Osteoarthristis Increases the Risk of Cardiovascular Disease: Data from the Osteoarthritis Initiative. J Nutr Health Aging. 2018;22(3):371-376. doi: 10.1007/s12603-017-0941-0.

Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21;387(10033): 2093-105. doi: 10.1016/S0140-6736(16)30002-2. Epub 2016 Mar 18.

Bjordal J, Klovning A, Ljunggren A, Slоrdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. Epub 2006 May 8.

Milder T, Lipworth W, Williams K, et al. «It looks after me»: How older patients make decisions about analgesics for osteoarthritis. Arthritis Care Res (Hoboken). 2011 Sep; 63(9):1280-6. doi: 10.1002/acr.20514.

Peloso PM, Moore RA, Chen WJ, et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scand J Pain. 2016 Oct;13: 175-181. doi: 10.1016/j.sjpain.2016.07.002. Epub 2016 Aug 10.

Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(S1):1-29. doi:10.14412/1995-4484-2018-1-29

Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2018;56(S1):1-29. (In Russ.). doi:10.14412/1995-4484-2018-1-29

Трифонова ЕП, Зонова ЕВ, Сазонова ОВ. Клинико-иммунологические особенности больных остеоартритом в сочетании с ожирением, метаболическим синдромом и сахарным диабетом 2-го типа. Сибирский медицинский журнал. 2017; (1):5-12.

Trifonova EP, Zonova EV, Sazonova OV. Clinical and immunological features of patients with osteoarthritis in combination with obesity, metabolic syndrome and type 2 diabetes. Sibirskii meditsinskii zhurnal. 2017;(1):5-12. (In Russ.).

Berenbaum F, Griffin TM, Liu-Bryan R. Review: Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol. 2017 Jan;69(1):9-21. doi: 10.1002/art.39842.

Zhang YM, Wang J, Liu XG. Association between hypertension and risk of knee osteoarthritis: A meta-analysis of observational studies. Medicine (Baltimore). 2017 Aug; 96(32):e7584. doi: 10.1097/MD.0000000000007584.

Mendy A, Park J, Vieira ER. Osteoarthritis and risk of mortality in the USA: a population-based cohort study. Int J Epidemiol. 2018 Aug 29. doi: 10.1093/ije/dyy187. [Epub ahead of print]

Kim SH, Yun JM, Chang CB, et al. Prevalence of upper gastrointestinal bleeding risk factors among the general population and osteoarthritis patients. World J Gastroenterol. 2016 Dec 28;22(48):10643-10652. doi: 10.3748/wjg.v22.i48.10643.

Vanderstraeten G, Lejeune TM, Piessevaux H, et al. Gastrointestinal risk assessment in patients requiring non-steroidal anti-inflammatory drugs for osteoarthritis: The GIRANO study. J Rehabil Med. 2016 Oct 5; 48(8):705-710. doi: 10.2340/16501977-2119.

Srinivasan A, De Cruz P. Review article: a practical approach to the clinical management of NSAID enteropathy. Scand J Gastroenterol. 2017 Sep;52(9):941-947. doi: 10.1080/00365521.2017.1335769. Epub 2017 Jun 6.

Küttner Magalhaes R, Ferreira JM, Pedroto I. Nonsteroidal anti-inflammatory drug (NSAID)-induced colopathy with diaphragm-like strictures. J Gastrointestin Liver Dis. 2014 Mar;23(1):9.

Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-241. doi: 10.1016/S2468-1253(18)30037-2. Epub 2018 Feb 21.

Wallace JL, Syer S, Denou E, de Palma G, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011 Oct;141(4):1314-22, 1322.e1-5. doi: 10.1053/j.gastro.2011.06.075. Epub 2011 Jul 13.

Emmanuel A, Mattace-Raso F, Neri MC, et al. Constipation in older people: A consensus statement. Int J Clin Pract. 2017 Jan; 71(1). doi: 10.1111/ijcp.12920. Epub 2016 Dec 9.

Day HD, Eckstrom E, Sullivan GM. Update in geriatric medicine. J Gen Intern Med. 2009 Mar;24(3):421-6. doi: 10.1007/s11606-009-0909-9. Epub 2009 Jan 29.

Kadam UT, Jordan K, Croft PR. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis. 2004 Apr;63(4):408-14.

Lembcke B. Diagnosis, Differential Diagnoses, and Classification of Diverticular Disease. Viszeralmedizin. 2015 Apr;31(2):95-102. doi: 10.1159/000380833. Epub 2015 Apr 29.

Драгунов ДО, Соколова АВ, Латышев ТВ, Арутюнов ГП. Распространенность хронической болезни почек у коморбидных пациентов. Клиническая нефрология. 2016;(3-4):49-52.

Dragunov DO, Sokolova AV, Latyshev TV, Arutyunov GP. Prevalence of chronic kidney disease in comorbid patients. Klinicheskaya nefrologiya. 2016;(3-4):49-52. (In Russ.).

Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3): 524-33. doi: 10.1161/HYPERTENSIONAHA.114.05105. Epub 2015 Jul 13.

Каратеев АЕ, Насонов ЕЛ. Мелоксикам в России: 20 лет вместе. Терапевтический архив. 2016;(12):149-58.

Karateev AE, Nasonov EL. Meloxicam in Russia: 20 years together. Terapevticheskii arkhiv. 2016;(12): 149-58. (In Russ.).

Xu S, Rouzer CA, Marnett LJ. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life. 2014 Dec; 66(12):803-11. doi: 10.1002/iub.1334. Epub 2014 Dec 23.

Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, doubleblind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000 Oct 23;160(19):2947-54.

Цветкова ЕС, Иониченок НГ, Карусинов ПС и др. Клинико-инструментальная оценка влияния фармакотерапии на течение остеоартроза коленных суставов. Научно-практическая ревматология. 2007; 45(1):69-74.

Tsvetkova ES, Ionichenok NG, Karusinov PS, et al.Clinical and instrumental assessment of the impact of pharmacotherapy on the course of osteoarthritis of the knee. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2007;45(1):69-74. (In Russ.)

Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNFalpha suppression. FASEB J. 2002 Mar;16(3): 438-40. Epub 2002 Jan 30.

Li H, Luo Y, Xu Y, et al.Meloxicam Improves Cognitive Impairment of Diabetic Rats through COX2-PGE2-EPs-cAMP/ pPKA Pathway. Mol Pharm. 2018 Sep 4; 15(9):4121-4131. doi: 10.1021/acs.molpharmaceut.8b00532. Epub 2018 Aug 23.

Katary MM, Pye C, Elmarakby AA. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels. Prostaglandins Other Lipid Mediat. 2017 Sep;132:3-11. doi: 10.1016/j.prostaglandins.2016.08.004. Epub 2016 Sep 3.

Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol. 2000 Dec;131(7):1413-21.

Rainsford KD, Ying C, Smith FC. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. J Pharm Pharmacol. 1997 Oct;49(10):991-8.

Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999 Dec 13;107(6A):48S-54S.

Singh G, Lanes S, Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic cpmplications with meloxicam. Am J Med. 2004 Jul 15; 117(2):100-6.

Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi: 10.1097/MD.0000000000001592.

Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription- event monitoring data. Rheumatology (Oxford). 2003 May;42(5):622-31.

Layton D, Hughes K, Harris S, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription- event monitoring (PEM) data. Rheumatology (Oxford). 2003 Nov;42(11): 1332-41. Epub 2003 Jun 16.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun; 22(6):559-70.

Asghar W, Jamali F. The effect of COX-2- selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.

Simionato LD, Petrone L, Baldut M, et al.Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina. Saudi Pharm J. 2018 May; 26(4):578-584. doi: 10.1016/j.jsps.2018.01. 015. Epub 2018 Feb 9.

Romani LFA, Yoshida MI, Gomes ECL, et al. Physicochemical characterization, the Hirshfeld surface, and biological evaluation of two meloxicam compounding pharmacy samples. J Pharm Anal. 2018 Apr;8(2):103-108. doi: 10.1016/j.jpha.2017.12.006. Epub 2017 Dec 19.

The authors declare that there are no conflicts of interest present.